Navigation Links
Mymetics Corporation Important Shareholders Information Conference Call
Date:8/25/2008

NYON, Switzerland, August 25 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC: MYMX), will be holding an important conference call on Wednesday August 27th 2008 at 1 PM New York Time to update all shareholders on the recent progress of the company, the June 30th 2008 Form 10-Q and to address recent press articles.

You may join the call Toll Free from the US at +1-866-591-4361 PIN 815 726 and from Europe at +41-800-329-326 PIN 815 726.

Corporate description:

Mymetics' primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase Ib clinical trials. Additional applications of Mymetics's research include potential treatments and/or vaccines for human oncoviral leukemias, multiple sclerosis, and organ transplantation.

Contact:

Anthony Jessop

Senior Vice President Mymetics, Inc.

Phone North America: +1-303-800-6606

E-Mail: ajessop@mymetics.com


'/>"/>
SOURCE Mymetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... 04, 2015 , ... November Research Group, LLC, a global ... to pharmaceutical and life sciences organizations, today announced the production implementation of its ... data intake solution that enables field sales representatives, clinical research associates, and product ...
(Date:9/3/2015)... 3, 2015 /PRNewswire/ - bioLytical Laboratories Inc., a leader ... study " Sensitivity of a rapid point of care ... its affinity for HIV gp41 IgM antibodies " has ... study highlights INSTI,s ability to detect early HIV infection.  ... the 8 th annual International AIDS Society Conference, ...
(Date:9/3/2015)... ... ... If you plan to attend the 27th annual Tradeline College and University ... up for the tour of Framingham State University's newest addition to Hemenway Hall taking ... (8) chemistry teaching labs that are exclusively utilizing (49) filtered fume hoods that ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biochips ... to their offering. This report is ... and applications. The report starts with a description ... markets. Technologies include array comparative genomic hybridization (CGH), ...
Breaking Biology Technology:November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2
... 28, 2012 Regado Biosciences, Inc., a privately held company ... announced that David J. Mazzo, PhD, President and CEO, will ... Annual Health Care Conference at 1:30 p.m. EST on March ... MA.  The presentation will include an overview ...
... ViroPharma Incorporated (Nasdaq: VPHM ) reported today its ... 31, 2011. In 2011, we: Achieved ... $251 million in net sales of Cinryze® (C1 esterase inhibitor ... Hydrochloride Capsules, USP); Attained non-GAAP adjusted net income of ...
... 28, 2012 Ultragenyx Pharmaceutical Inc., a biotechnology ... ultra-rare genetic disorders, today announced that the FDA ... drug designation for UX003 for the treatment of ... autosomal recessive lysosomal storage disorder characterized by a ...
Cached Biology Technology:Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 2Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 12Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... A new study has found that the allergenicity of ... fermentation process. Researchers from North Carolina A&T University report ... the American Society for Microbiology. , "Due to the ... cookies, snacks and even soups there is a need ...
... viral-based therapies for cancer , Researchers at Columbia University ... to develop the next generation of effective viral-based therapies ... genetically engineered viruses studied in mice, published today in ... National Academy of Sciences (PNAS), bring us significantly closer ...
... have had an accelerated childhood compared to that of modern ... by researchers from Ohio State University and the University of ... tooth growth present in the Neanderthal fossils they examined was ... , And since the rate of tooth growth has ...
Cached Biology News:Columbia scientists develop cancer terminator viruses 2Columbia scientists develop cancer terminator viruses 3Neanderthal teeth grew no faster than comparable modern humans' 2Neanderthal teeth grew no faster than comparable modern humans' 3
... The DNA Engine Tetrad thermal cycler ... the pioneering PTC-200 DNA Engine cycler. ... the capacity with a footprint only ... throughput for laboratories that run massive ...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... PROTEAN II xi multi-cell is for 2-D separations. ... cooling capabilities. The PROTEAN II xi multi-cell can ... type of glass plates, and cooling system. The ... to the PROTEAN II XL multi-cell for a ...
Biology Products: